SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-048943
Filing Date
2019-02-25
Accepted
2019-02-25 06:24:38
Documents
5
Period of Report
2019-02-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d711494d8k.htm 8-K 37724
2 EX-2.1 d711494dex21.htm EX-2.1 482656
3 EX-3.1 d711494dex31.htm EX-3.1 2882
4 EX-99.1 d711494dex991.htm EX-99.1 15379
5 GRAPHIC g711494g0225074602622.jpg GRAPHIC 2606
  Complete submission text file 0001193125-19-048943.txt   543689
Mailing Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104
Business Address 3737 MARKET STREET SUITE 1300 PHILADELPHIA PA 19104 888-772-7560
Spark Therapeutics, Inc. (Filer) CIK: 0001609351 (see all company filings)

IRS No.: 462654405 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36819 | Film No.: 19628022
SIC: 2836 Biological Products, (No Diagnostic Substances)